@article{5d7b9e5c8bce4d6db1f4f0584420834c,
title = "Jak1 Integrates Cytokine Sensing to Regulate Hematopoietic Stem Cell Function and Stress Hematopoiesis",
abstract = "JAK1 is a critical effector of pro-inflammatory cytokine signaling and plays important roles in immune function, while abnormal JAK1 activity has been linked to immunological and neoplastic diseases. Specific functions of JAK1 in the context of hematopoiesis, and specifically within hematopoietic stem cells (HSCs), have not clearly been delineated. Here, we show that conditional Jak1 loss in HSCs reduces their self-renewal and markedly alters lymphoid/myeloid differentiation in vivo. Jak1-deficient HSCs exhibit decreased competitiveness in vivo and are unable to rescue hematopoiesis in the setting of myelosuppression. They exhibit increased quiescence, an inability to enter the cell cycle in response to hematopoietic stress, and a marked reduction in cytokine sensing, including in response to type I interferons and IL-3. Moreover, Jak1 loss is not fully rescued by expression of a constitutively active Jak2 allele. Together, these data highlight an essential role for Jak1 in HSC homeostasis and stress responses. Selective JAK1 inhibition has emerged as a potential strategy for treating autoimmune and hematological diseases. Levine and colleagues show that Jak1 integrates multiple cytokine signals in normal and malignant HSCs to regulate their self-renewal and quiescence, highlighting further potential therapeutic benefits and risks of Jak1 inhibition.",
keywords = "Jak1, cytokine signaling, hematopoietic stem cells, stress hematopoiesis",
author = "Maria Kleppe and Spitzer, {Matthew H.} and Sheng Li and Hill, {Corinne E.} and Lauren Dong and Efthymia Papalexi and {De Groote}, Sofie and Bowman, {Robert L.} and Matthew Keller and Priya Koppikar and Rapaport, {Franck T.} and Julie Teruya-Feldstein and Jorge Gandara and Mason, {Christopher E.} and Nolan, {Garry P.} and Levine, {Ross L.}",
note = "Funding Information: The authors thank members of the Levine and Nolan laboratories for helpful comments and discussion. This work was supported by NCI R35-CA197594-01A1 and NCI CA173636 to R.L.L.; K99 HL122503-01A1 to M. Kleppe; NIH F31 CA189331 to M.H.S.; NIH R01 CA196657 , U19 AI057229 , U19 AI100627 , R33 CA183654 , R01 HL120724 , DOD grants OC110674 and 11491122 , Bill and Melinda Gates Foundation grant OPP1113682 , NIAID Bioinformatics Support Contract HHSN272201200028C , and FDA grant 30 HHSF223201210194C BAA-12-00118 to G.P.N. S.L. is supported by grants from the Ty Louis Campbell Foundation and the WorldQuant Foundation . Technical services provided by the MSKCC Core Facilities were supported in part by MSKCC Support Grant/Core Grant P30 CA008748 . R.L.L. is a Leukemia and Lymphoma Society Scholar . M. Kleppe is a fellow of the American Society of Hematology and was previously supported by fellowships from the Leukemia and Lymphoma Society and the European Molecular Biology Organization . G.P.N. is a consultant for Fluidigm and the maker of CyTOF. R.L.L. is a consultant for Novartis and is on the Supervisory Board of QIAGEN. Publisher Copyright: {\textcopyright} 2017 Elsevier Inc.",
year = "2017",
month = oct,
day = "5",
doi = "10.1016/j.stem.2017.08.011",
language = "English",
volume = "21",
pages = "489--501.e7",
journal = "Cell Stem Cell",
issn = "1934-5909",
publisher = "Cell Press",
number = "4",
}